Lilly gains license for Ascidian's gene-editing tech to develop kidney disease drugs

Ascidian Therapeutics said on Wednesday it has signed a licensing deal for its gene-editing technology with pharma major Eli ​Lilly , worth up to $1.9 billion, to develop new therapies for rare ‌inherited kidney diseases.